Pharmacogenomics: implementation and cost-effectiveness evaluation

• Grant number: 19/08338-7
• Support Opportunities: Regular Research Grants
• Start date: April 01, 2020
• End date: September 30, 2022
• Field of knowledge: Biological Sciences - Pharmacology - General Pharmacology
• Principal Investigator: Paulo Caleb Júnior de Lima Santos
• Grantee: Paulo Caleb Júnior de Lima Santos
• Host Institution: Instituto Nacional de Farmacologia (INFAR). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• City of the host institution: São Paulo

Abstract

In a current review about pharmacogenomics studies in Brazil, authors showed that there are several retrospectives studies focusing on the drugs and genes. However, no prospective analyses of drug therapy outcomes or cost-effectiveness assessments of pharmacogenomics-guided therapy were found at 2018. Last years, we organized lab logistics and clinical multidisciplinary professional to perform prospective studies in pharmacogenomics, beside cost-effectiveness analysis. The present project, to the best of our knowledge, has prospective and pioneer studies to evaluate cost-effectiveness in Brazil. Our main results of the previous grant have already published approximately 40 scientific papers (listed in an attached document). The present application will show 2 proposed subprojects, item by item, for easing the understanding. 1- For the implementation and cost-effectiveness evaluation of a pharmacogenetic-based warfarin dosing algorithm: we will check if this implementation is advantageous and we will measure the quality of this treatment (by TTR) and, thus, we can estimate a possible decreasing of thromboembolism and bleeding events, which can indicate better costs. 2- For the implementation and cost-effectiveness evaluation of genetic markers in the choice of the pharmacological treatment of smoking: since there are financial difficulties for the treatment of smokers, we could be more effective and economical in order to achieve greater success and larger numbers of patients treated. (AU)

Scientific publications

(8)

(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)

STEINER, HEIDI E.; GILES, JASON B.; PATTERSON, HAYLEY KNIGHT; FENG, JIANGLIN; EL ROUBY, NIHAL; CLAUDIO, KARLA; MARCATTO, LEILIANE RODRIGUES; TAVARES, LETICIA CAMARGO; GALVEZ, JUBBY MARCELA; CALDERON-OSPINA, CARLOS-ALBERTO; et al. Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. FRONTIERS IN PHARMACOLOGY, v. 12, OCT 29 2021. (16/23454-5, 13/09295-3, 19/08338-7)

DE FARIA, HENRIQUE DIPE; SILVEIRA, ALBERTO THALISON; DO PRADO, BEATRIZ CARVALHO; MOREIRA NACIF, JULIA LOUISE; ROSA, MARIANA AZEVEDO; DOS SANTOS, JULIANA DA ROCHA; LIMA SANTOS, PAULO CALEB JUNIOR; FIGUEIREDO, EDUARDO COSTA; MARTINS, ISARITA. Online biological sample preparation with restricted access hybrid carbon nanotubes for determination of anti-smoking drugs. Journal of Chromatography A, v. 1669, p. 14-pg., 2022-04-26. (19/08338-7)

DE LARA, DANILO VIEIRA; DE MELO, DANIELA OLIVEIRA; ARAUJO SILVA, LUCAS CAETANO; GONCALVES, THUANE SALES; JUNIOR LIMA SANTOS, PAULO CALEB. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews. PHARMACOGENOMICS, v. 23, n. 7, p. 10-pg., 2022-04-05. (19/08338-7)

ALINE MORGAN ALVARENGA; NATHÁLIA KOZIKAS DA SILVA; RODOLFO DELFINI CANÇADO; LUÍS EDUARDO MORATO REBOUÇAS DE CARVALHO; PAULO CALEB JUNIOR LIMA SANTOS. Brazilian family with hyperferritinemia-cataract syndrome: case report. Einstein (São Paulo), v. 20, 2022-10-24. (19/08338-7)

TOMAZ, PAULO ROBERTO XAVIER; GONCALVES, THUANE SALES; SANTOS, JULIANA ROCHA; SCHOLZ, JAQUELINE; ABE, TANIA OGAWA; GAYA, PATRICIA VIVIANE; FIGUEIREDO, EDUARDO COSTA; DE FARIA, HENRIQUE DIPE; MARTINS, ISARITA; PEGO, ANA MIGUEL FONSECA; et al. Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion. FRONTIERS IN PHARMACOLOGY, v. 13, p. 7-pg., 2022-07-22. (19/08338-7)

MARCATTO, LEILIANE RODRIGUES; SACILOTTO, LUCIANA; TAVARES, LETICIA CAMARGO; PEREIRA SOUZA, DEBORA STEPHANIE; OLIVETTI, NATALIA; CASSARO STRUNZ, CELIA MARIA; COSTA DARRIEUX, FRANCISCO CARLOS; SCANAVACCA, MAURICIO IBRAHIM; KRIEGER, JOSE EDUARDO; PEREIRA, ALEXANDRE COSTA; et al. Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. FRONTIERS IN PHARMACOLOGY, v. 11, JUL 14 2020. (16/23454-5, 16/22507-8, 13/09295-3, 19/08338-7)

SANTOS, JULIANA ROCHA; XAVIER TOMAZ, PAULO ROBERTO; SCHOLZ, JAQUELINE RIBEIRO; GAYA, PATRICIA VIVIANE; ABE, TANIA OGAWA; KRIEGER, JOSE EDUARDO; PEREIRA, ALEXANDRE COSTA; DE LIMA SANTOS, PAULO CALEB JUNIOR. Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment. GENES, v. 11, n. 7, JUL 2020. (13/09295-3, 19/08338-7)

DE LARA, DANILO VIEIRA; DE MELO, DANIELA OLIVEIRA; KAWAKAMI, DANIELE Y.; GONCALVES, THUANE S.; SANTOS, PAULO C. J. L.. Pharmacogenetic testing-guided treatment for oncology: an overview of reviews. PHARMACOGENOMICS, v. 23, n. 13, p. 10-pg., 2022-08-24. (19/08338-7)